Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Decreases Neurofilament Light Chain Levels Over 2.5 Years of Treatment in Patients with Relapsing Multiple Sclerosis
Titel:
Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Decreases Neurofilament Light Chain Levels Over 2.5 Years of Treatment in Patients with Relapsing Multiple Sclerosis